Generate-Boost: study protocol for a prospective, multicenter, randomized controlled, double-blinded phase II trial to evaluate efficacy and safety of bortezomib in patients with severe autoimmune encephalitis

BACKGROUND: Autoimmune encephalitis is a new spectrum of autoimmune disorders of the central nervous system (CNS), which are characterized by pathogenic autoantibodies against neuronal surface antigens. Clinical presentations range from acute to subacute encephalopathy with neurological and psychiat...

Descripción completa

Detalles Bibliográficos
Autores principales: Wickel, Jonathan, Chung, Ha-Yeun, Platzer, Stephanie, Lehmann, Thomas, Prüss, Harald, Leypoldt, Frank, Günther, Albrecht, Scherag, André, Geis, Christian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346383/
https://www.ncbi.nlm.nih.gov/pubmed/32641101
http://dx.doi.org/10.1186/s13063-020-04516-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7346383/
https://www.ncbi.nlm.nih.gov/pubmed/32641101
http://dx.doi.org/10.1186/s13063-020-04516-7

Ejemplares similares